For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
PARTNER 3 Trial
The purpose of this trial is to determine the safety and effectiveness of an aortic valve device in patients with severe narrowing of the aortic valve that are deemed low operative risk for standard surgical aortic valve replacement (SAVR). The main goals are to successfully place the aortic valve device, relieving or possibly eliminating the narrowing in the valve, while avoiding complications.
In order to participate you must meet the following criteria:
- Have aortic valve stenosis.
- Are symptomatic from aortic valve stenosis.
- Considered low risk for surgery as patients will be randomized to either transcatheter aortic valve replacement (TAVR) or surgery.
- Agree to comply with all required post-procedure follow-up visits including annual visits through ten years and analysis close date visits.
This is a partial list of eligibility requirements.